Asset Details
Do you wish to reserve the book?
Healthy tissue metabolism assessed by 18FFDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Healthy tissue metabolism assessed by 18FFDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients
Do you wish to request the book?
Healthy tissue metabolism assessed by 18FFDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Healthy tissue metabolism assessed by 18FFDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients
2024
Overview
The aim of the study was to assess healthy tissue metabolism (HTM) using 2-deoxy-2-[
18
F]fluoro-D-glucose ([
18
F]FDG) positron emission tomography/computed tomography (PET/CT) during chemotherapy in Hodgkin lymphoma (HL) and the association of HTM with baseline metabolic tumour volume (MTV), haematological parameters, adverse events (AEs), early response and progression-free survival (PFS). We retrospectively identified 200 patients with advanced HL from the RATHL trial with [
18
F]FDG-PET/CT before (PET0) and following 2 cycles of chemotherapy (PET2). [
18
F]FDG-uptake was measured in bone marrow (BM), spleen, liver and mediastinal blood pool (MBP). Deauville score (DS) 1–3 was used to classify responders and DS 4–5, non-responders. [
18
F]FDG-uptake decreased significantly in BM and spleen and increased in liver and MBP at PET2 (all
p
< 0.0001), but was not associated with MTV. Higher BM uptake at PET0 was associated with lower baseline haemoglobin and higher absolute neutrophil counts, platelets, and white blood cells. High BM, spleen, and liver uptake at PET0 was associated with neutropenia after cycles 1–2. BM uptake at PET0 was associated with treatment failure at PET2 and non-responders with higher BM uptake at PET2 had significantly inferior PFS (
p
= 0.023; hazard ratio = 2.31). Based on these results, we concluded that the change in HTM during chemotherapy was most likely a direct impact of chemotherapy rather than a change in MTV. BM uptake has prognostic value in HL.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Bone Marrow - diagnostic imaging
/ Female
/ Glucose
/ Hodgkin Disease - diagnostic imaging
/ Hodgkin Disease - drug therapy
/ Hodgkin Disease - metabolism
/ Humanities and Social Sciences
/ Humans
/ Liver
/ Lymphoma
/ Male
/ Positron emission tomography
/ Positron Emission Tomography Computed Tomography - methods
/ Science
/ Spleen
We currently cannot retrieve any items related to this title. Kindly check back at a later time.